Balancing Innovation & Access: EU Expert Panel's Advice On Pricing Models
Executive Summary
An EU expert panel has come up with some ideas for new payment models that member state authorities might like to consider when negotiating the prices of innovative new medicines.
You may also be interested in...
Drug Pricing Alliances Expand In Europe
Slovenia has joined the Valletta group, with Croatia set to follow. Meanwhile, Ireland has formally signaled its interest in joining the BeNeLuxA collaboration.
MEPs And Health Advocates Pile The Pressure On EU Drug Pricing
A European Parliament committee has approved a report outlining some possible solutions to the question of access to expensive new drugs, while Health Action International and several other NGOs have put emphasis on the need to ensure that where drugs developed by private companies use publicly funded research, they really serve the public good.
EU’s Unitary SPC System Must Maximize Access To Medicines & Not Block Generic Entry
A European Parliament committee says that some aspects of the EU’s proposed unitary supplementary protection certificate scheme could promote access to cheaper off-patent medicines while others could delay generic competition.